HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma (Q36100243)

12 August 2017

title

HER-2/neu expression as a predictor of response to neoadjuvant docetaxel in patients with operable breast carcinoma (English)

1 reference

12 August 2017

1 reference

Peter A Learn

1

1 reference

12 August 2017

I-Tien Yeh

2

1 reference

12 August 2017

Michelle McNutt

3

1 reference

12 August 2017

Gary B Chisholm

4

1 reference

12 August 2017

Brad H Pollock

5

1 reference

12 August 2017

Dennis L Rousseau

6

1 reference

12 August 2017

Frances E Sharkey

7

1 reference

12 August 2017

Anatolio B Cruz

8

1 reference

12 August 2017

Morton S Kahlenberg

9

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 June 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

103

1 reference

12 August 2017

issue

11

1 reference

12 August 2017

page(s)

2252-2260

1 reference

Preoperative/neoadjuvant medical therapy for early breast cancer

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

International expert panel on the use of primary (preoperative) systemic treatment of operable breast cancer: review and recommendations

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Neoadjuvant docetaxel for operable breast cancer induces a high pathological response and breast-conservation rate

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Neoadjuvant chemotherapy for operable breast carcinoma larger than 3 cm: a unicentre randomized trial with a 124-month median follow-up. Institut Bergonié Bordeaux Groupe Sein (IBBGS)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

A prospective trial of preoperative chemotherapy in resectable breast cancer: predictors of breast-conservation therapy feasibility

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Randomized trial of chemoendocrine therapy started before or after surgery for treatment of primary breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Effect of preoperative chemotherapy on the outcome of women with operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Prognostic factors for survival after neoadjuvant chemotherapy in operable breast cancer. the role of clinical response

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Systematic review of taxane-containing versus non-taxane-containing regimens for adjuvant and neoadjuvant treatment of early breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Overexpression of both p185c-erbB2 and p170mdr-1 renders breast cancer cells highly resistant to taxol

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Resistance to taxanes is induced by c-erbB-2 overexpression in human MCF-10A mammary epithelial cells and is blocked by combined treatment with an antisense oligonucleotide targeting type I protein kinase A.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Neoadjuvant trastuzumab and docetaxel in breast cancer: preliminary results

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Lack of association between amplification of her-2 and response to preoperative taxanes in patients with breast carcinoma

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Role of proliferation in HER2 status predicted response to doxorubicin.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Comparison of Topoisomerase-IIα Gene Status between Primary Breast Cancer and Corresponding Distant Metastatic Sites

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

When is a tumor marker ready for prime time? A case study of c-erbB-2 as a predictive factor in breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Influence of endocrine-related factors on response to perioperative chemotherapy for patients with node-negative breast cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.21037

7 January 2021

Identifiers

DOI

10.1002/CNCR.21037

1 reference

12 August 2017

1 reference